Bupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution Specifications
Sun Pharmaceutical is recalling nationwide certain lots of Bupropion Hydrochloride Extended-Release Tablets 150 mg because tablets from these lots failed to meet dissolution specifications during stability testing, potentially affecting drug effectiveness.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall without reported illnesses or injuries. The hazard involves compromised drug efficacy where reduced effectiveness poses a risk of harm even though injury has not yet been reported, fitting the criteria for High severity.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling 5,344 bottles of Bupropion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg (NDC 47335-737-86) nationwide in the United States.
The recall was initiated because certain lots failed to meet dissolution specifications during stability testing. Dissolution testing measures whether tablets release the active ingredient at the proper rate. When tablets fail this test, the medication may not be absorbed as intended, potentially affecting its effectiveness.
The affected lots are HAC2240A (expiration 05/2023) and HAC3162A (expiration 07/2023). Patients currently taking affected tablets should consult their healthcare provider or pharmacist to determine the appropriate next steps.
The recalled product
- Product
- BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)
- Brand
- BUPROPION HYDROCHLORIDE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug
- Affected units
- 5,344
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: HAC2240A
- Exp 05/2023
- HAC3162A
- Exp 07/2023
UPCs (2)
- 0347335738865
- 0347335737868
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUPROPION HYDROCHLORIDE
- ModerateBupropion extended release tablets recalled after failing tablet specifications
FDA (Drugs) · 2025-10-29
- HighBupropion Extended-Release Tablets Recalled for Dissolution Failure
FDA (Drugs) · 2024-07-17
- HighFDA recalls Bupropion Hydrochloride tablets for foreign tablet contamination
FDA (Drugs) · 2024-01-17
- ModerateBupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-12-13
- ModerateSun Pharmaceutical Bupropion Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-10-25
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22